Thrombus - 2010


The new NICE VTE guideline – a clinical auditor’s view
Beverly Ryton
pp 1-1
The recently released clinical guideline, Venous thromboembolism – reducing the risk, is an update of a previous guideline, originally released in 2007. As such, the NHS will have been working towards implementing the original guideline recommendations.
Comment: When increasing guidance is not so NICE
Peter Rose
pp 2-2
The increase in guidance should be a positive development and, in this issue, we are to have insights into the latest improvements on guidelines on lupus anticoagulant screening and atrial fibrillation. January 2010 also saw the publication of the National Institute for Health and Clinical Excellence (NICE) Guideline 92 Venous thromboembolism – reducing the risk.
The new NICE VTE guideline – a surgeon’s perspective
Simon Frostick
pp 3-4
Not all NICE guidelines are welcomed. However, the 2010 NICE guideline for venous thromboembolism (VTE) in patients admitted to hospital should be accepted as a comprehensive and practical guide to reducing the risk of a potentially preventable complication.
The new NICE VTE guideline – a pharmacist’s opinion
Omar Ali
pp 5-5
The recent NICE VTE guideline embraces QIPP – Quality, Innovation, Productivity, Prevention. The pharmacy profession in secondary (and, increasingly, in primary) care is directly involved in delivering NHS prioritisation from the beginning to the end of the VTE patient pathway, via the QIPP agenda.
Guidelines for thrombophilia testing
Trevor Baglin
pp 6-8
Testing for laboratory evidence of heritable thrombophilia is now common. This practice undoubtedly arose in response to association studies, which revealed the influence of heritable thrombophilia on the development of venous thromboembolism (VTE).
Treating elderly patients with atrial fibrillation: aspirin versus warfarin
Duncan Edwards and Jonathan Mant
pp 9-10
Atrial fibrillation (AF) carries a risk of thromboembolic stroke that increases with age. There is strong evidence that warfarin reduces this risk more than aspirin. However, the majority of elderly patients (over the age of 75) are not currently taking warfarin, due to a perceived higher risk of haemorrhage, and inconvenience of monitoring.
UK Thromboprophylaxis Forum: hospital-acquired thrombosis issues
Peter Rose
pp 12-12
The second UK Thromboprophylaxis Forum was held at the Royal Society of Medicine on 19 March 2010 and was very well attended, with delegates from a wide spectrum of backgrounds. The thrust of the meeting was to present the latest National Institute for Health and Clinical Excellence (NICE) guidance (CG92) around hospital thromboprophylaxis and to see how implementation can be achieved and monitored through a national venous thromboembolism (VTE) prevention strategy.
Nursing programme at the ISTH: Boston, 2009
Caroline Baglin
pp 13-13
A nursing component of the International Society on Thrombosis and Haemostasis (ISTH) congress was first established at the meeting held in Sydney, Australia in 2005. It was then included at the Geneva, Switzerland meeting two years later, and again at the 22nd congress of the ISTH in Boston, USA in July 2009. At the Boston meeting, 22 countries were represented, and the nursing programme included both abstract submissions and oral presentations. A formal nursing workshop was held on each day of the meeting.
Dangers of alcohol abuse and warfarin
Christina Sleep
pp 14-15
A 67-year-old male was referred to the outpatient anticoagulation service by his GP after being diagnosed with permanent atrial fibrillation (AF) – a common condition that is a major risk factor for stroke. Approximately 5% of NHS expenditure can be attributed to the management of patients who have had a stroke, and about 1,000 new cases are expected each year in a typical health authority with a population of around 500,000.

Thrombus is funded by an unrestricted educational grant from Bayer HealthCare, with no editorial input into the contents of this journal.

Thrombus was previously supported by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Group Ltd and, together with the content, is bound by copyright. Copyright © 2017 Hayward Group Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)